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DNA immunization induces B and T cell responses to various 
pathogens and tumors. However, these responses are known 
to be relatively weak and often transient. Thus, novel strat-
egies are necessary for enhancing immune responses in-
duced by DNA immunization. Here, we demonstrated that 
co-immunization of influenza virus nucleoprotein (NP) gene 
significantly enhances humoral and cell-mediated responses 
to codelivered antigens in mice. We also found that NP DNA 
coimmunization augments in vivo proliferation of adoptively 
transferred antigen-specific CD4 and CD8 T cells, which en-
hanced protective immunity against tumor challenge. Our re-
sults suggest that NP DNA can serve as a novel genetic ad-
juvant in cocktail DNA vaccination.
[Immune Network 2009;9(5):169-178]
INTRODUCTION
DNA vaccines provide several advantages over live attenuated 
or  vectored  vaccines;  relatively  safe,  easy  to  manufacture, 
easy  formulation  of  multivalent  vaccines,  and  the  induction 
of  type  1  CD4
＋  T  cell-mediated  immune  responses  (1-3). 
However, it has been shown that DNA vaccine alone is un-
able  to  confer  complete  protection  against  some  infectious 
pathogens, due to its relatively weak immunogenicity, partic-
ularly in large animal model (1,4,5). To overcome the poor 
immunogenicity, codelivery of plasmid DNA encoding various 
adjuvant molecules has been  used to augment the immune 
responses elicited by DNA immunization. For example, cyto-
kines such as IL-2 (6), IL-12 (7,8), and GM-CSF (9,10) have 
been  shown  to  efficiently  enhance  antigen-specific  immune 
responses  induced  by  DNA  vaccine.  Co-stimulatory  mole-
cules, such as B7.1, B7.2 and CD40L, have been also found 
to increase antigen-specific T-cell responses by enhancing an-
tigen-presenting cells’ (APC) functions (11-13). However, the 
use of cytokine/co-stimulatory molecules as genetic adjuvants 
could raise safety concern, since relatively little information 
is available on their long-term safety in humans (14). Also, 
DNA  vaccines  formulated  in  either  a  solution  containing  a 
nonionic blocked copolymer adjuvant (CRL 1005) or in mono-
phosphoryl  lipid  A  adsorbed  onto  aluminium  phosphate 
(MPL/alum) appeared to enhance vaccine-elicited cellular im-
mune  response  against  co-delivered  antigens  like  SIV  Gag 
(15). DNA itself could be used to enhance immunogenicity 
if  it  contains  cytidine-phosphate-guanosine  (CpG)  motif, 
which is known to stimulate innate immune system (16,17).   
Indeed,  HIV-1  specific  cytotoxic  T-lymphocyte  (CTL)  re-
sponse and humoral response are enhanced by the coimmu-
nization  of  DNA  containing  the  CpG  motif  (18,19). 
    One of the most beneficial things about DNA vaccination 
i s  t h e  f a c t  t h a t  s e v e r a l  p l a s m i d  v e c t o r s  c a n  b e  e a s i l y  f o r -
mulated into a single inoculum to induce multivalent immune 
r e s p o n s e s  t o  v a r i o u s  a n t i g e n s  s i m u l t a n e o u s l y .  I t  h a s  b e e n  
well  demonstrated  that  immunization  of  a  mixture  of  plas-
mids, called cocktail DNA vaccination, induces broad immune 
responses to multiple-antigens in DNA vaccine models (20). 
H o w e v e r ,  i t  r e m a i n s  t o  b e  e l u c i d a t e d  w h e t h e r  t h e  a d m i n -Influenza Virus NP Gene as a Genetic Adjuvant
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istration of a cocktail DNA vaccine results in immune interfer-
ence or enhancement to each other. For example, Kjerrstrom 
et al. reported that immunization with a mixture of plasmids 
encoding the HIV regulatory genes tat, rev, and nef resulted 
in  reduced  T-cell  responses  to  Rev  and  Nef,  compared  to 
those observed in single gene immunization (21). These re-
sults suggest that specific immune response to an antigen may 
inhibit other responses to codelivered antigens in a multigene 
vaccine. In contrast, another study by Grifantini et al. showed 
that  poor  immunogenicity  of  plasmid  encoding  major  mer-
ozoite  surface  protein  (MSP)-1  were  enhanced  in  cocktail 
DNA  vaccination  compared  with  those  in  a  single  plasmid 
DNA  immunization  (22).
    In  this  study,  we  found  that  coimmunization  of  the  NP 
gene significantly enhances specific humoral and cellular im-
mune responses to various DNA-encoded antigens. In addi-
tion, NP DNA coimmunization elicited faster and vigorous in 
vivo proliferation of adoptively transferred CD8 T cells and 
CD4 T cells specific for codelivered ovalbumin (OVA) anti-
gen,  and  more  efficient  protection  against  modified  tumor 
challenge than single OVA DNA immunization. Our findings 
suggest  that  the  NP  gene  could  function  as  a  genetic 
adjuvant. 
MATERIALS AND METHODS
Construction of plasmids
MDCK cells were infected with influenza A/PR/8/34 virus and 
influenza  A/Jap/57 viruses,  respectively, and total RN A was 
isolated. The NP gene of influenza A/PR/8/34 and the hemag-
glutinin (HA) gene of Influenza A/Jap/57 were then obtained 
by conducting RT-PCR with the isolated RNA. These NP and 
HA genes, cleaved by XhoI/XbaI and KpnI/Xho I, were in-
serted into pTV2 vector (9) to prepare pTV-NP and pTV-HA, 
respectively. pTX-GE (6), cleaved by MluI and HpaI, was in-
serted into pTV2 vector to prepare pTV-GE. pTV-gDsE2t ex-
pressing  truncated  HCV  E2  protein  is  described  elsewhere 
(9). Chicken OVA cDNA from Tc-OVA vector was amplified 
by PCR and inserted into pTV2 vector to prepare pTV-OVA. 
Each plasmid DNA was grown in E. coli and then purified 
using endotoxin-free kits (QIAGEN, Valencia, CA). Endotoxin 
levels were measured using Limulus Amebocyte Lysate assay 
(Sigma,  St.  Louis,  MO)  and  were  typically  negligible  in  all 
DNA preparations. The expression of NP was identified using 
anti-Flu  (A/PR/8/34)  mouse  serum  by  the  radioimmuno-
precipitation method in transient transfection assay. The ex-
pressions  of  pTV-OVA  and  pTV-GE  were  confirmed  by 
Western  blot  analysis  as  described  previously  (6). 
Immunization 
Six  to  seven  week-old  female  mice  (BALB/c  or  C57BL/6), 
purchased from crSLC, Japan, were used for the DNA immu-
nization  experiments.  Plasmids  were  dissolved  in  PBS  at  a 
concentration of 1 mg/ml, and a total of 100 μg DNA was 
intramuscularly injected into the tibials muscle in both hind 
legs of BALB/c mice (50 μl in each leg). Four weeks after 
the  first  immunization,  a  booster  immunization  was  per-
formed at the same region using the same DNA vaccines. For 
coimmunization with OVA DNA and NP DNA, C57BL/6 mice 
were used in intramuscular immunization. In cases of single 
DNA immunization, 50 μg of pTV empty vector were used 
to  adjust  the  total  amount  of  injected  DNA  to  100  μg.
Antibody ELISA 
HA and NP protein were partially purified from an Influenza 
bulk vaccine (LG Chemical Co. Ltd., Korea) using a Con-A 
Cephalos  column  (Amersham  Biosciences,  Piscataway,  NJ), 
according to the manufacturer’s instruction. Each protein sol-
ution was separated by SDS-PAGE. Gels corresponding to NP 
and HA protein bands were cut out and electroeluted for use 
as  NP  and  HA  antigens  in  ELISA.  Antibody  responses  to 
HIV-1 structural protein and HCV E2 protein were measured 
by ELISA using HIV-1 viral lysate (6) and hghE2t protein (9). 
Mice sera were collected 4 weeks after final immunization to 
determine  the  anti-HA,  anti-Env  or  anti-E2  response.  ELISA 
was  used  to  detect  antibody  response,  as  described  pre-
viously  (23).
CTL assay
CTL activity was measured by using a conventional 
51Cr re-
lease assay. Four weeks after the booster immunization, sple-
nocytes of mice in each group were prepared and maintained 
in a CTL analysis culture medium (RPMI 1640 supplemented 
with 10% FBS, 2 mM L-glutamine, 50 μM β-mercaptoetha-
nol,  and  10  U/ml  recombinant  murine  IL-2).  To  stimulate 
NP-specific  and  HA-  specific  lymphocytes,  cells  were  in-
cubated with 7 μM of each peptide at 37
oC in 5% CO2 for 
6  days.  P815  (H-2
d) target cells  were  pulsed  with  5μM  of 
NP  (TYQRTRALV)  or  HA  peptide  (LYQNVGTYV),  labeled 
with 
51Cr,  and  reacted  with  the  stimulated  effector  cells  to 
measure cytotoxicity. To stimulate the HIV env-specific CTLs, 
the irradiated splenocytes of non-immunized BALB/c mice in-Influenza Virus NP Gene as a Genetic Adjuvant
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fected  with  a  recombinant  vaccinia  virus  expressing  HIV-1 
(IIIB) env (National Institutes of Health AIDS Research and 
Reference Reagent Program) were used as a stimulator. The 
splenocytes of the immunized mice were cultivated for 6 days 
together with the stimulator cells, and then reacted with V3 
peptide (RIQRGPGRAFVTIGK) pulsed-P815 target cells. HCV 
E2-specific  CTL  response  was  measured  as  described  pre-
viously  (24). 
ELISPOT assay
IFN-γ ELISPOT assay was performed as described previously 
(25). Briefly, splenocytes were serially two- fold diluted start-
ing with 4×10
5 cells per well on IFN-γ capture mAb (5 μg/ 
ml,  BD  Pharmingen,  San  Diego,  CA)-coated  nitrocellulose 
96-well plates (Millipore, Bedford, MA), in triplicate, and 10 
μM each of OVA 257-264 (SIINFEKL, H-2K
b-restricted), OVA 
323-339  peptide  (ISQAVHAAHAEINEAGR,  I-A
b  restricted),  5
μM of NP peptide (ASNENMETM, H-2D
b-restricted), or HIV-1 
V 3  p e p t i d e  ( R I Q R G P G R A F V T I G K ,  D
d-restricted)  was  then 
added. After incubation at 37
oC in 5% CO2 for 24 h, the plates 
were washed 5 times with PBS containing 0.05% Tween 20 
(PBST) and treated with 2.5 μg/ml of biotin-conjugated an-
ti-IFN-γ detection mAb (BD Pharmingen) followed by strep-
tavidin-conjugated alkaline phosphatase. The BCIP/ NBT sub-
strates were then added to the plates, and the reaction was 
terminated with excess water when blue spots were observed 
after several minutes. The number of spots was counted us-
ing  an  ELISPOT  reader  (AID).
Adoptive transfer and FACS analysis 
TCR-transgenic T cells from OT-I or OT-II mice (26), which 
are  specific  to  the  OVA  257-264  or  the  OVA  323-339,  re-
spectively,  were  used  as  donor  cells  in  adoptive  transfer 
experiments. A single cell suspension was obtained from the 
lymph nodes of 6-week-old OT-I or OT-II mice, and treated 
with  anti-HSA  (J11d),  anti-B220,  anti-MHC  class  II,  and  an-
ti-CD4 microbead antibodies for CD8 T cells (or anti-CD8 for 
CD4  T  cells)  at  4
oC  for  30  minutes,  and  then  treated  with 
a rabbit complement at 37
oC for 45 minutes to obtain OT-I 
( o r  O T - I I )  c e l l s  a t  a  p u r i t y  o f  m o r e  t h a n  9 5 % .  M i c r o b e a d s  
were obtained from Miltenyi Biotec (Auburn, CA). The puri-
fied cells were resuspended in PBS at a concentration of 2 
×10
7 cells/ml, and labeled with 5 μM of CFSE (Molecular 
Probes,  Eugene,  OR)  to  trace  cell  division  in  vivo. T h e  l a-
beled cells were then transferred into 6 to 7-week-old female 
C57BL/6  mice.  After  24h,  the  recipient  mice  were  intra-
muscularly  injected  with  plasmid  DNA,  and  cells  from  the 
draining lymph nodes of each mouse were prepared 9 days 
after immunization. Cells were stained with PerCP-conjugated 
anti-CD4 or CD8 mAb (BD Pharmingen, SanDiego, CA) and 
PE-conjugated  Vα2  mAb  (BD  Pharmingen)  at  4
oC  for  15 
minutes. Finally, 50,000∼100,000 cells were collected using 
FACSCalibur  (BD  Biosciences, S a n  J o s e ,  C A )  a n d  a n a l y z e d  
with  CellQuest  software  (BD  Biosciences). 
Tumor challenge
OVA-specific CD8 T cells from the lymph nodes of six-week- 
old  OT-I  mice  were  purified  by  negative  selection  using 
MACS,  as  described  above,  and  adoptively  transferred  into 
n o r m a l  m i c e .  A t  d a y  1 ,  e a c h  p l a s m i d  D N A  w a s  i n t r a m u s -
cularly  injected  into  the  mice.  The  DNA-immunized  mice 
were subcutaneously injected with EG-7 tumor cells (5×10
5 
cells/mouse in 100 μl of PBS) expressing OVA after 28 days. 
The tumor size was regularly checked using microcaliper at 
the indicated time points. Percentage of tumor incidence was 
represented as the population of mice bearing palpable tu-
mors  (tumor  volume＞40  mm
3). 
RESULTS
Antigen-specific humoral and cell-mediated responses 
was enhanced by coinjection of influenza NP DNA
DNA immunization with a mixture of plasmids encoding in-
fluenza HA and NP has been known to induce more effective 
protection against influenza virus infection than that with a 
single plasmid (27). However, it remains unknown whether 
the enhanced protection is associated with varied breadth and 
strength  of  immune  responses.  In  this  study,  we  evaluated 
the possibility that immune response to specific antigen eli-
cited by DNA immunization could be modulated by coimmu-
nized  DNA  in  cocktail  DNA  vaccine  model.  To  this  end, 
pTV-NP, pTV-HA, or a mixture of pTV-HA and pTV-NP were 
injected into female BALB/c mice twice at four-week interval. 
Interestingly,  anti-HA  antibodies  in  mice  immunized  with 
pTV-HA DNA were nearly detectable, but were significantly 
enhanced by coinjection with pTV-NP DNA (p＜0.005, Fig. 
1A). Similarly, CTL  response  to  HA antigen,  but not  to NP 
antigen, were enhanced by coinjection of pTV-HA and pTV- 
NP  compared  with  by  single  DNA  immunization  (Fig.  1B). 
As a control, mice immunized with pTV-NP DNA alone did 
not induce HA-specific antibody and CTL immune responses, 
and vice versa (Fig. 1A, and data not shown), indicating the Influenza Virus NP Gene as a Genetic Adjuvant
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Figure 1. Increased antigen-specific antibody and CTL responses by NP DNA coimmunization. The plasmid vectors encoding the influenza viruses
HA (A/Jap/57), HIV Env (HXBc2) and HCV E2 (genotype 1b) were mixed with NP (A/PR/8/34) or mock DNA, and then intramuscularly injected 
twice, at four-week interval, into female BALB/c mice. Antibody (A) and CTL responses (B) to HA, HIV Env, and HCV E2 were analyzed 4 
weeks after the boost immunization. (A) Sera from the immunized mice were diluted to 1/100 and antibody responses were determined by 
ELISA assay. Circles represent O.D. at 405 nm and the bars are the means of four mice per group. Data are representative of two independent 
experiments. *p＜0.05, **p＜0.005 (B) Splenocytes from two mice per group were pooled and the specific killing of HA peptide-loaded P815 
target cells was determined by standard 
51Cr release assay. Killing of P815 target cells without HA peptide was ＜2%. rVV Env-infected naive 
syngeneic splenocytes and P815 cells were used as stimulator and target cells, respectively, for determining HIV Env-specific CTL response. 
An E2-expressing CT26 cell line was used as stimulator and target cells for measuring HCV E2-specific CTL activity. Non-specific killing of target
cells without Env or E2 was ＜5%. Similar data were obtained in three separate experiments. (C) HIV Env-specific T-cell responses were measured
by ELISPOT assay. Each group of mice were immunized twice with pTV-GE in the absence or presence of pTV-NP at 0 and 6 weeks. At the 
indicated time points, pooled splenocytes were prepared and Env-specific IFN-γ responses to V3 peptide were analyzed. Values represent the 
means±s.d. of triplicate cultures in one experiment. Similar data were obtained in three separate experiments. **p＜0.005, ***P＜0.001, 
Statistical significance was determined using the Student t test.
absence  of  cross-reactivity  between  these  two  antigens.
  T o  i n v e s t i g a t e  w h e t h e r  t h i s  a d j u v a n t i c i t y  o f  i n f l u e n z a  N P  
DNA is broadly applicable to other antigen in DNA vaccine 
model, a plasmid DNA encoding HIV gag-env (pTV-GE) or 
HCV E2 (pTV-gDsE2t) was injected with or without pTV-NP 
twice  into  female  BALB/c  mice  at  four-week  interval. 
Antibody and CTL responses to HIV Env and HCV E2 were 
determined at 4 weeks after booster immunization using se-Influenza Virus NP Gene as a Genetic Adjuvant
So Young Choi, et al.
173 IMMUNE NETWORK http://www.ksimm.or.kr Volume 9 Number 5 October 2009
Figure 1. Continued.
rum and splenocytes from the immunized mice, respectively. 
As expected, anti-Env and anti-E2 antibody responses were 
significantly enhanced by coinjection with pTV-NP DNA (p＜ 
0.005 and p＜0.05, respectively, Fig. 1A). Similarly, Env- and 
E2-specific  CTL  responses  determined  by  using  a  conven-
tional 
51Cr  release  assay  were  enhanced  by  codelivery  of 
pTV-NP DNA (Fig. 1B). Immunization of pTV-NP DNA alone 
did not induce Env- or E2-specific immune response, and vice 
versa. Furthermore, coimmunization of pTV-NP-R which has 
NP gene in a reverse orientation failed to increase immune 
response to codelivered antigen (data not shown), suggesting 
that the enhancement is not presumably due to potent stim-
ulating CpG motifs within NP gene. On the other hand, NP- 
specific antibody and CTL responses were not affected by co-
injection  with  pTV-GE  DNA  or  pTV-gDsE2t  DNA  (data  not 
shown).  Since  endotoxin  is  able  to  enhance  DNA-encoded 
antigen-specific immune responses, the endotoxin level in NP 
DNA  purified  by  ultrapure  endotoxin-free  DNA  purification 
kit  (QIAGEN)  was  measured  and  shown  to  be  less  than  3 
endotoxin units (EU)/μg DNA for in vivo use. In addition, 
there was no significant difference in the endotoxin level in 
each plasmid DNA. Thus, it is unlikely that endotoxin con-
tamination contributes to the effect of NP DNA on immune 
enhancement. These results clearly indicate that NP gene spe-
cifically  enhances  antibody  and  CTL  responses  to  a  broad 
range of codelivered antigens in DNA vaccination model. It 
is worth noting that the individual difference of CTL response 
appeared to be less than of antibody response because sple-
n o c y t e s  w e r e  p o o l e d  f o r  C T L  a s s a y .  
    The longevity of immune responses induced by vaccination 
is one of the most critical parameters in determining the effi-
cacy of vaccines. To determine whether the coadministration 
of NP DNA elicits sustained immune responses specific to co-
delivered antigen, two groups of mice were injected twice at 
0  and  6  weeks  with  pTV-GE  with  or  without  pTV-NP.  As 
shown in Fig. 1C, the frequency of HIV Env-specific IFN-γ- 
p r o d u c i n g  c e l l s  d e t e r m i n e d  b y  E L I S P O T  a s s a y  w a s  s i g n i -
ficantly increased by codelivery of NP DNA at 5 weeks after 
the first immunization and 4 and 8 weeks after the booster 
immunization (10 and 14 weeks, p＜0.005 and p＜0.001, re-
spectively). These results suggest that NP DNA coimmuniza-
tion not only enhances antibody and CTL responses but also 
prolongs memory T-cell immunity to specific antigen induced 
by  DNA  immunization.
Enhancement of OVA-specific immune responses 
correlated with injection doses of NP DNA
To define dose-dependence in immune enhancement by NP 
DNA,  female  C57BL/6  mice  were  immunized  with  50  μg 
pTV-OVA plus various concentration of NP DNA (from 0 to 
100  μg)  and  then  the  induction  of  OVA-specific  CD4  and 
CD8 T cells was quantitatively determined by ELISPOT assay 
using  OVA  (323-339:  I-A
b-restricted)  and  OVA  (257-264: 
H-2K
b-restricted) peptide, respectively, at 4 weeks after boos-
ter immunization. As shown in Fig. 2A, coinjection of pTV- 
OVA  even  with  5  μg  of  pTV-NP  induced  higher  numbers 
of OVA-specific IFN-γ-producing CD4 and CD8 T cells than 
that by pTV-OVA alone and peak responses were observed 
with 50 μg of NP DNA (Fig. 2A). It was previously reported 
that  the  frequency  of  memory  T  cells  is  dependent  on  the 
initial  burst  size  of  the  primary  effector  cells  (28).  Thus,  it 
is likely that enhancement of memory T cell immunity by NP 
DNA coinjection is due to increase of the primary expansion 
of  codelivered  antigen-specific  T  cells. 
Frequency and proliferation of OVA-specific T cells 
were increased by coinjection of NP DNA 
To investigate the adjuvant effect of NP DNA on proliferation 
of antigen-specific T cells, purified naive OVA-specific OT-I 
and OT-II cells were labeled with the fluorescent dye, CFSE, 
a n d  t h e n  a d o p t i v e l y  t r a n s f e r r e d  i n t o  f e m a l e  C 5 7 B L / 6  m i c e .  
One  day  later,  mice  were  immunized  with  pTV-NP,  or 
pTV-OVA, or a mixture of pTV-NP and pTV-OVA. At 9 days 
post-immunization,  draining lymph  node  cells  from the  im-
munized mice were analyzed for in vivo proliferation of do-
nor OT-I and OT-II cells by flow cytometry. OT-I cells from 
mice coimmunized with pTV-NP and pTV-OVA appeared to Influenza Virus NP Gene as a Genetic Adjuvant
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Figure 2. Increased frequency and proliferation of OVA-specific CD4 and CD8 T cells by coimmunization of NP DNA. (A) Plasmid DNA encoding
OVA was mixed with different doses of NP DNA(5, 20, 50, and 100μg) or mock DNA, and then intramuscularly injected into female C57BL/6
mice. At 4 weeks after booster DNA immunization, pooled splenocytes were prepared from two mice per group. Cells were stimulated with 
OVA (257-264: H-2K
b-restricted epitope) or OVA (323-339: class II-restricted epitope) peptides and analyzed for IFN-γ-producing T cells by 
ELISPOT assay. Values represent the means ± s.d. of triplicate cultures in one experiment. The experiment was repeated three times and produced 
similar results. (B, C) CFSE-labeled naive OT-I and OT-II cells (2×10
6) were adoptively transferred into C57BL/6 mice and then one day later 
OVA DNA was intramuscularly injected with or without NP DNA. At day 9 post-immunization, pooled draining inguinal lymph nodes from 
two mice per group were analyzed by measuring the in vivo proliferation of (B) OT-I and (C) OT-II cells by flow cytometry. Live lymphocytes 
were gated according to forward and side light scatter profiles. Data are representative of three independent experiments that produced similar 
results. Influenza Virus NP Gene as a Genetic Adjuvant
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Figure 3. NP DNA coinjection enhances protection against tumor 
challenge. Naive. OT-I cells (2×10
6) were adoptively transferred into
C57BL/6 mice and the DNA encoding OVA was intramuscularly 
injected with or without NP DNA one day later (n=12). At 28 days
post-immunization, mice were s.c. inoculated with 5×10
5 EG-7 tumor
cells. Tumor sizes were measured using microcaliper in two 
dimensions. The populations of mice bearing palpable tumors (tumor
volume＞40 mm
3) are presented as the percentage of tumor 
incidence. Coimmunization of OVA DNA and NP DNA showed the
reduced level of tumor incidence (p＜0.01, Student t test).
proliferate more extensively than those with pTV-OVA alone, 
although both of them displayed the same number of division 
cycles  (i.e.,  more  than  five  times)  (Fig.  2B).  In  particular, 
proliferation of transferred OT-II cells was notably enhanced 
in the presence of pTV-NP (Fig. 2C). It is worth noting that 
OVA  DNA  immunization  alone  is  able  to  induce  weak  but 
significant  proliferation  of  adoptively  transferred  OT-I  cells, 
but not OT-II cells. These results are consistent with reported 
that the proliferation of naive CD4 T cells requires 100-fold 
higher  levels of  antigenic stimulation  than that required for 
naïve CD8 T cell proliferation  in vitro a nd  in vivo (29,30). 
As a negative control, transferred OT-I and OT-II cells did not 
proliferate when mice were immunized with pTV-NP alone 
(Fig.  2B). 
Enhancement of protection against tumor challenge 
I t  h a s  b e e n  k n o w n  t h a t  n o t  o n l y  H A - s p e c i f i c  a n t i b o d y  a n d 
CTL  responses  but  also  NP-specific  CTL  response  are  im-
portant  for  protection  against  influenza  virus  infection  (31, 
32). Thus, if the protective immunity induced by NP＋HA co-
delivery is stronger than that by NP or HA single immuniza-
tion,  it  is  not  clear  whether  the  protection  is  due  to  either 
the broad immunity to influenza NP and HA or the enhance-
ment of HA-specific immune response by codelivery of NP 
DNA as adjuvant. Accordingly, it is likely that the use of tu-
mor challenge model instead of influenza challenge is more 
appropriate to show the adjuvant effect of NP DNA in DNA 
immunization model. Therefore, to determine whether the in-
creased frequency of antigen-specific T cells by codelivery of 
NP DNA correlates with in vivo protection against tumor chal-
lenge, C57BL/6 mice were adoptively transferred with naive 
OT-I  cells  and  then  intramuscularly  injected  with  pTV-OVA 
DNA in the presence or absence of NP DNA one day after 
adoptive transfer. At 28 days post-immunization, the immu-
nized mice were challenged with EG-7 tumor cells expressing 
OVA and tumor growth was examined. As expected, tumor 
g r o w t h  w a s  s i g n i f i c a n t l y  d e l a y e d  a n d  t u m o r  i n c i d e n c e  w a s  
only 17% of mice coimmunized with pTV-NP and pTV-OVA 
(p＜0.01)  (Fig.  3).  Interestingly,  pTV-OVA-immunized  mice 
also  showed  delayed  tumor  growth,  compared  with  the 
pTV-NP-immunized mice as a control. However, pTV-OVA- 
immunized  group  eventually  exhibited  the  same  tumor  in-
cidence as control mice (50%) at day 30 after tumor challenge. 
Taken together, these results suggest that the enhanced pro-
liferation and frequency of antigen-specific T cells induced by 
the codelivery of NP DNA increases protection against tumor 
challenge. 
DISCUSSION
It has been shown that influenza NP DNA immunization in-
duces  relatively  potent  humoral  and  cellular  immune  re-
sponses  to  NP  protein,  suggesting  that  NP  has  strong  im-
munogenicity (33,34). In general, it is believed that immune 
response  is  decreased  by  antigen  competition  when  highly 
immunogenic  antigens  are  coadministered.  Upon  virus  in-
fection, immune responses to dominant epitopes of the viral 
antigen  are  known  to  interfere  with  the  induction  of  sub-
dominant  and/or  cryptic  epitope-specific  responses  (35-37). 
Moreover, it has been suggested that coinfection with highly 
immunogenic viruses causes immune interference rather than 
immune enhancement (35). However, in the present study, 
we showed that NP gene can serve as a genetic adjuvant in 
multigene  DNA  immunization  models,  augmenting  codeliv-
ered antigen-specific antibody and T cell responses. Since our 
results  somehow  contrast  with  the previous observations in 
a virus infection model, it is likely that there are marked dif-
ferences in the outcomes of antigen-specific immune competi-
tion between virus infection and DNA vaccine model, which 
would  be  derived  from  the  different  environments  of  both Influenza Virus NP Gene as a Genetic Adjuvant
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systems, such as location and expression level of antigen, the 
presence of CpG motif (18,38), and the replication ability of 
the vector. As agreed with our results, when the MN V3 re-
gion of HIV-1 was fused with HBV surface antigen (HBsAg), 
the V3-specific antibody and CTL responses were enhanced, 
as compared with the results of immunization with MN gp160 
DNA (39). This study suggests that highly immunogenic anti-
gen like HBsAg acts as “a fused adjuvant”, which augments 
and  accelerates  cellular  and  humoral  immune  response 
against  other  antigens  in  DNA  vaccine  model. 
  L i k e  g e n e t i c  m o d u l a t o r s  s u c h  a s  c y t o k i n e s  a n d  c o s t i m u -
latory molecules, it is possible that the adjuvant effect of NP 
gene is due to the induction of a beneficial microenvironment 
for the optimal activation of codelivered antigen-specific na-
ive T cells by potent NP-specific immunity. NP-specific T cells 
induced by NP DNA coinjection cause the activation and ma-
turation  of  cognate  or  noncognate  dendritic  cells  either  by 
providing CD40L signaling or by secreting immunostimulatory 
soluble factors, as described in previous reports (40). The li-
censed dendritic cells in the microenvironment may in turn 
enhance the magnitude of T-cell responses specific for code-
livered target antigens. In addition, given that the induction 
of CTL responses depends on cognate CD4 T cell help in a 
DNA vaccine model, the CD4 T cell responses which were 
significantly enhanced by codelivery of pTV-NP might be in-
v o l v e d  i n  t h e  e f f e c t  o f  N P  g e n e  p r o d u c t .  T h u s ,  i t  i s  l i k e l y  
that potent NP-specific T-cell immunity decreases the thresh-
old levels for activation and proliferation of naive CD4 T cells, 
which is known to be more difficult than those of naive CD8 
T cells (30). CD8＋ CTLs are known to be capable of potent 
anti-tumor immune response (41). Our results show that en-
hancement  of  OVA-specific  CD8  T  cell  frequency  and  pro-
liferation induced by NP DNA codelivery promotes protective 
immunity  against  tumor  challenge.  The  data  suggested  that 
the ability of NP DNA to enhance broad immune responses 
make it a potent adjuvant for enhancing protective efficacy 
requiring  humoral  or  cellular  immunity.
    In summary, we show that the NP gene has a potent genet-
ic adjuvant effect on a broad range of codelivered antigens. 
This information will be of help on the design of formulations 
in  the  effective  cocktail  DNA  vaccines,  considering  the  im-
munogenic  potential  of  each  codelivered  plasmid-encoded 
antigen. 
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